# 510(k) Summary

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 (317)-521-3532

Contact person: Randy J. Johnson

Date Prepared: March 6, 2006

# Device Name

Proprietary name: (1) Elecsys ACTH Immunoassay () Elecsys ACTH CalSet (3) Elecsys ACTH CalCheck (4) Elecsys PreciControl ACTH

Common name: (1) ACTH Assay ACTH CalSet (3) ACTH CalCheck (4) PreciControl ACTH

Classification name: (1) System, Test, ACTH ) Calibrator, Secondary (3 & 4) Single (specified) analyte controls (assayed and unassayed)

# 510(k) Summary, Continued

# Device Description

(1) The Elecsys ACTH Assay is a two step sandwich immunoassay with streptavidin microparticles and electrochemiluminescence detection. Results are determined using a calibration curve that is generated specifically on each instrument by a 2 point calibration and a master curve provided with the reagent bar code.

(2) The Elecsys ACTH CalSet is a lyophilized product consisting of equine serum with added ACTH in two concentration range. During manufacture, the analyte is spiked into the matrix at the desired concentration levels.

(3) The Elecsys ACTH CalCheck is a lyophilized product consisting of buffered equine serum with added ACTH. During manufacture, the analyte is spiked into the matrix at the desired concentration levels.

(4) The Elecsys PreciControl ACTH is a lyophilized product consisting of equine serum with added ACTH in two concentration ranges. During manufacture, the analyte is spiked into the matrix at the desired concentration levels.

control are all packaged separately.

# Intended use

(1) Elecsys ACTH Reagent: Immunoassay for the in vitro quantitative determination of adrenocorticotropic hormone (ACTH) in human EDTA plasma. The electrochemiluminescence immunoassay "ECLIA" is intended for use on the Roche Elecsys 1010/2010 and MODULAR ANALYTICS E 170 (Elecsys module) immunoassay analyzers.

Elecsys ACTH CalSet is used for calibrating the quantitative Elecsys ACTH assay on the Elecsys immunoassay analyzers.

()Elecsys ACTH CalCheckFor use in the verication of the calibrain established by the Elecsys ACTH reagent on Elecsys 1010/2010 and MODULAR E170 immunoassay analyzers.

(4) Elesys PreciControl ACTH is used for quality control of the Elecsys ACTH immunoassay on the Elecsys immunoassay analyzers.

# 510(k) Summary, Continued

# Indications for Use

(1) Elecsys ACTH Reagent: Immunoasssay for the in vitro quantitative determination of adrenocorticotropic hormone (ACTH) in human EDTA plasma. The electrochemiluminescence immunoassay "ECLIA" is intended for use on the Roche Elecsys 1010/2010 and MODULAR ANALYTICS E 170 (Elecsys module) immunoassay analyzers. ACTH measurments are used in the differential diagnosis and treatment of certain disorders of the adrenal glands such as Cushings syndrome, adrenocortical insufficiency, and the ectopic ACTH syndrome.

(2) Elecsys ACTH CalSet is used for calibrating the quantitative Elecsys ACTH assay on the Elecsys immunoassay analyzers.

(3) Elecsys ACTH CalCheck: For use in the verification of the calibration established by the Elecsys ACTH reagent on Elecsys 1010/2010 and MODULAR E170 immunoassay analyzers.

(4) Elesys PreciControl ACTH is used for quality control of the Elecsys ACTH immunoassay on the Elecsys immunoassay analyzers.

# Substantial equivalence

The Elecsys ACTH Test System is substantially equivalent to other devices legally marketed in the United States.

(1) Elecsys ACTH Immunoassay is equivalent to the Immulite ACTH assay (K960066). Both products are intended for use in the quantitative determination of ACTH in plasma.

() Elecsys ACTH CalSet is equivalent to the Immulite ACTH assay (K960066).

(3) Elecsys ACTH CalCheck is equivalent to the Elecsys Prolactin II CalCheck (K053059).

(4) Elecsys PreciControl ACTH is equivalent to the Elecsys PreciControl Troponin T (K031990).

# 510(k) Summary, Continued

# Substantial equivalence - similarities

Continued on next page   

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature </td><td rowspan=1 colspan=1>Elecsys ACTH</td><td rowspan=1 colspan=1>Predicate DeviceImmulite ACTH Assay</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Immunoassay for the in vitroquantitative determination ofadrenocorticotropic hormone(ACTH) in human EDTA plasma.The electrochemiluminescenceimmunoassay &quot;ECLIA&quot; is intendedfor use on the Roche Elecsys1010/2010 and MODULARANALYTICS E 170 (Elecsysmodule) immunoassay analyzers.</td><td rowspan=1 colspan=1>For in vitro diagnostic use with theImmulite 2000 analyzer - for thequantitative measurement ofadrenocorticotropic hormone in EDTA,plasma, as an aid in the assessment ofadrenal insufficiency andhypersecretion</td></tr><tr><td rowspan=1 colspan=1>Indication forUse</td><td rowspan=1 colspan=1>ACTH measurements are used inthe differential diagnosis andtreatment of certain disorders of theadrenal glands such as Cushingssyndrome, adrenocorticalinsufficiency, and the ectopicACTH syndrome.</td><td rowspan=1 colspan=1>As an aid in the assessment of adrenalinsufficiency and hypersecretion.</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Sandwich assay</td><td rowspan=1 colspan=1>Solid-phase, two site</td></tr><tr><td rowspan=1 colspan=1>DetectionProtocol</td><td rowspan=1 colspan=1>ElectrochemiluminescentImmunoassay</td><td rowspan=1 colspan=1>Chemiluminescent immunometricassay</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human plasma treated with K3-EDTA</td><td rowspan=1 colspan=1>Human plasma treated with EDTA</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>ACTH CalSet</td><td rowspan=1 colspan=1>ACTH Adjustors (LACL, LACH)</td></tr></table>

# 510(k) Summary, Continued

<table><tr><td rowspan=1 colspan=3>Substantial equivalence - similarities, continued</td></tr><tr><td rowspan=1 colspan=3>CalSet Comparison</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys ACTH CalSet</td><td rowspan=1 colspan=1>Predicate DeviceImmulite ACTH Assay</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Used for calibrating the quantitativeElecsys ACTH assay on the Elecsysimmunoassay analyzers.</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Two</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>CalCheck Comparison</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys ACTH CalCheck</td><td rowspan=1 colspan=1>Predicate DeviceElecsys Prolactin II CalCheck</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Three</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 2-8°C up to the printedexpiration date on the bottle labelsReconstituted:15 - 25 °C : 4 hrs</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=2>PreciControl Comparison</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys ACTH PreciControl</td><td rowspan=1 colspan=1>Predicate DeviceElecsys PreciControl Troponin T</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Two</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Dissolve carefully the contents of onebottle by adding exactly 2.0 mL ofdistilled water and allow to standclosed for 15 minutes to reconstitute.Mix carefully, avoiding the formationof foam.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td></tr></table>

# 510(k) Summary, Continued

<table><tr><td rowspan=1 colspan=3>Substantial equivalence - difierences</td></tr><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys ACTH</td><td rowspan=1 colspan=1>Predicate DeviceImmulite ACTH Assay</td></tr><tr><td rowspan=1 colspan=1>Traceability Standardization</td><td rowspan=1 colspan=1>Standardized gravimetrically withsynthetic ACTH produced at Roche.</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>CalibrationInterval</td><td rowspan=1 colspan=1>E170/Elecsys 2010:After 1 month (28 days) when usingthe same reagent lot.After 7 days (when using the samereagent kit on the analyzer).Elecsys 1010:With every reagent kit.After 7 days (20-25°C).After 3 days (25-32°C).</td><td rowspan=1 colspan=1>Every four weeks.</td></tr><tr><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>Roche Elecsys 1010/2010 andMODULAR ANALYTICS E170(Elecsys module) analyzers.</td><td rowspan=1 colspan=1>Immulite 2000 Analyzer</td></tr><tr><td rowspan=1 colspan=1>CalibrationVerification</td><td rowspan=1 colspan=1>ACTH CalCheck</td><td rowspan=1 colspan=1>None stated in the package insert.</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>PreciControl ACTH</td><td rowspan=1 colspan=1>LACCM: Bi-level ACTH controlmodule (protein based)..</td></tr><tr><td rowspan=1 colspan=1>Reagent Stability</td><td rowspan=1 colspan=1>Unopened:2-8° - Up to the stated expirationdateOpened:2-8°C - 12 weeksOn the E170 / Elecsys 2010 - 4weeksOn the Elecsys 1010: - 4 weeks(stored alternately in the refrigeratorand on the analyzer- ambienttemperature 20-25°C; up to 20 hoursopened in total.)</td><td rowspan=1 colspan=1>ACTH Reagent Wedge:Stable at 2 - 8°C until the expirationdate.</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>1 - 2,000 pg/mL</td><td rowspan=1 colspan=1>5- 1,250 pg/mL</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalence - differences   

<table><tr><td colspan="4">Immunoassay Comparison</td></tr><tr><td colspan="4">Feature Elecsys ACTH Predicate Device Immulite ACTH Assay</td></tr><tr><td>Precision</td><td>Elecsys 1010/2010: Within-run</td><td colspan="2"></td></tr><tr><td rowspan="10">Total 5.4% CV @ 2.4% CV @ 2.6% CV @ E170:</td><td rowspan="10">2.9% CV @ 2.0% CV @ 2.1% CV @ 1.5% CV @ 115 pg/mL 1.6% CV @ 970 pg/mL</td><td rowspan="10">Intra-assay:</td><td></td></tr><tr><td>4.9 pg/mL 8.7% CV @</td></tr><tr><td>23 pg/mL 74.2 pg/mL 6.7% CV @ 30 pg/mL</td></tr><tr><td>1,390 pg/mL 6.8% CV @ 40 pg/mL</td></tr><tr><td>6.9% CV @ 208 pg/mL 9.5% CV @ 421 pg/mL</td></tr><tr><td>Interassay: 4.9 pg/mL 10.0% CV @ 24 pg/mL 44 pg/mL</td></tr><tr><td>74.2 pg/mL 8.2% CV @ 1,390 pg/mL 8.7% CV @</td></tr><tr><td>1.7% CV @ 115 pg/mL 9.3% CV @ 229 pg/mL 1.8% CV @ 970 pg/mL 6.1% CV @ 496 pg/mL</td></tr><tr><td></td></tr><tr><td colspan="2">Within-run 2.7% CV @ 4.9 pg/mL 0.6% CV @ 0.7% CV @</td></tr><tr><td colspan="2">0.6% CV @ sensitivity (LDL)</td><td colspan="2">64.3 pg/mL 1,205 pg/mL 111 pg/mL 968 pg/mL</td></tr><tr><td colspan="2">1.2% CV @ Total 5.4% CV @</td><td></td></tr><tr><td colspan="2"></td><td colspan="2"></td></tr><tr><td colspan="2">4.96 pg/mL</td><td colspan="2"></td></tr><tr><td colspan="2">3.5% CV @ 3.7% CV @ 1.8% CV @</td><td></td></tr><tr><td colspan="2"></td><td>76.1 pg/mL</td></tr><tr><td colspan="2">Analytical</td><td>1,444 pg/mL 114 pg/mL</td></tr><tr><td colspan="2"></td><td>972 pg/mL</td></tr><tr><td colspan="2"></td><td></td></tr><tr><td colspan="2">2.0% CV @</td><td></td></tr><tr><td colspan="2">1.0 pg/mL</td><td>5 pg/mL</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalence - differences   

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys ACTH</td><td rowspan=1 colspan=1>Predicate DeviceImmulite ACTH Assay</td></tr><tr><td rowspan=1 colspan=1>MethodComparison(LinearRegression)</td><td rowspan=1 colspan=1>Elecsys ACTH (y) versus acommercially available ACTH test(x):y= 0.90x + 8.17, r = 0.992, n=180</td><td rowspan=1 colspan=1>DPC Immulite 2000 versus DPCImmulite:(IML 2000) = 0.95 (IML) + 2.9 pg/mLr = 0.988, n = 86</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSpecificity</td><td rowspan=1 colspan=1>No cross reactivity for:ACTH (1-10)ACTH (11-24)Beta MSHBeta EndorphinACTH fragments:(ACTH 1-17, ACTH 1-24, ACTHCLIP 18-39, ACTH 22-39, AlphaMSH 1-13) &gt; 5,000 pg/mL can bindto one of the antibodies and therebynegatively interfere with thesandwich formation and lead tolower ACTH values.Under ACTH (1-24) medication,ACTH measurement is notrecommended. POMC (partiallypurified from an adenoma cell line)showed an approximate 1.6% cross-reactivity at 1,560 pmol/L which isapproximately forty times thephysiological concentration ofACTH precursors in circulation.</td><td rowspan=1 colspan=1>No cross reactivity for:ACTH (1-18)Cross reactivity:ACTH (1-24)ACTH (1839)Alpha MSH</td></tr><tr><td rowspan=1 colspan=1>Hook Effect</td><td rowspan=1 colspan=1>No high dose hook effect up to1,000,000 pg/mL</td><td rowspan=1 colspan=1>No high dose hook effect up to1,500,000 pg/mL</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalence - differences   

<table><tr><td colspan="3">Immunoassay Comparison Predicate Device</td></tr><tr><td colspan="3">Feature Elecsys ACTH</td></tr><tr><td rowspan="3">Limitations</td><td>The assay is unaffected by: Icterus (bilirubin &lt;428 μmol/L or &lt;25 mg/dL</td><td>Immulite ACTH Assay The assay is unaffected by: Bilirubin: (Up to 200 mg/L)</td></tr><tr><td>Hemolysis (&lt;0.25 mmol/L or &lt;0.4 g/dL) Lipemia (Intralipid &lt; 1,500 mg/dL) Biotin (&lt;246 nmol/L or , 60 ng/mL)</td><td>Hemolysis: (Up to 512 mg/dL) Lipemia: (Triglycerides up to 5,000 mg/dL)</td></tr><tr><td>In patients receiving therapy with high biotin doses (i.e &gt; 5 mg/day), no sample should be taken until at least 8 hours after the last biotin administration No interference was observed from rheumatoid factors up to a concentration of 400 IU/mL In vitro tests were performed on 17 commonly used pharmaceuticals. No interference was found with the assay Under ACTH 1-24 medication,</td><td>Heterophilic antibodes in human serum can react with the immunoglobulins included in the assay components causing interference with in vitro immunoassays. Samples from patients routinely exposed to animals or animal serum products can demonstrate this type of interference potentially causing an anomalous result. These reagents have been formulated to minimize the risk of interference, however, potential interactions between rare</td></tr></table>

510(k) Summary, Continued

Substantial equivalence - differences   

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys ACTH</td><td rowspan=1 colspan=1>Predicate Devicemmulite ACTH Assay</td></tr><tr><td rowspan=1 colspan=1>Limitations</td><td rowspan=1 colspan=1>Erroneous findings may beobtained from samples takenfrom patients who have beentreated with monoclonalantibodies or have receivedthem for diagnostic purposes.In rare cases, interference dueto extremely high titers ofantibodies to ruthenium canoccur. Elecsys ACTH containsadditives which minimize theseeffects.Extremely high titers ofantibodies to streptavidin canoccur in isolated cases andcause interference.For diagnostic purposes, theresults should always beassessed in conjunction with thepatient&#x27;s medical history,clinical examination and otherfindings</td><td rowspan=1 colspan=1>For diagnostics purposes, the resultsobtained from this assay shouldalways be used in combination withthe clinical examination, patientmedical history, and other findings.</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalence - differences   

<table><tr><td rowspan=1 colspan=3>CalSet Comparison</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsy ACTH CalSet</td><td rowspan=1 colspan=1>Predicate devicemmulite ACTH Assay</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Equine serum</td><td rowspan=1 colspan=1>Bovine protein-based</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 2-8°C until expirationdate.Reconstituted or thawed:2-8°C: 1 week-20°C: 3 months (freeze onlyonce)•on Elecsys 1010/2010 at 20-25°C: Up to 5 hourson E170: Use only once</td><td rowspan=1 colspan=1>Reconstituted:-20°C: 2 months</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Dissolve carefully the contents ofone bottle by adding exactly 1.0mL of distilled water and allow tostand closed for 15 minutes toreconstitute. Mix carefully,avoiding the formation of foam.</td><td rowspan=1 colspan=1>Reconstitute each vial with 4.0 mLdistilled or deionized water. Let standfor 30 minutes, then mix by gentleswirling or inversion.</td></tr></table>

510(k) Summary, Continued

Substantial equivalence - differences   

<table><tr><td rowspan=1 colspan=3>CalCheck Comparison</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys ACTH CalCheck</td><td rowspan=1 colspan=1>Predicate deviceElecsys Prolactin II CalCheck</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For use in the verification of thecalibration established by theElecsys ACTH reagent on Elecsys1010/2010 and MODULAR E170immunoassay analyzers.</td><td rowspan=1 colspan=1>For use in the verification of thecalibration established by the ElecsysProlactin II reagent on Elecsys1010/2010 and MODULARANALYTICS E170 immunoassayanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Buffered equine serum withsynthetic 1-39 ACTH.</td><td rowspan=1 colspan=1>Buffered equine serum withrecombinant human Prolactin from E.Coli</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Reconstitute the contents withexactly 2.0 mL distilled water ordeionized water. Allow the bottleto stand closed for 15 minutes. Mixby inversion to ensurehomogeneity.</td><td rowspan=1 colspan=1>Reconstitute the contents with exactly1.0 mL distilled or deionized water.Allow the bottle to stand closed for 15minutes. Mix by inversion to ensurehomogeneity.</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Standardized gravimetrically withsynthethic ACTH produced atRoche.</td><td rowspan=1 colspan=1>Standardized against the 3&quot;d IRP WHOReference Standard 84/500.</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalence - differences   

<table><tr><td rowspan=1 colspan=3>CalCheck Comparison</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys ACTH CalCheck</td><td rowspan=1 colspan=1>Predicate deviceElecsys Prolaetin II CalCheck</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For use in the verification of thecalibration established by theElecsys ACTH reagent on Elecsys1010/2010 and MODULAR E170immunoassay analyzers.</td><td rowspan=1 colspan=1>For use in the verification of thecalibration established by the ElecsysProlactin II reagent on Elecsys1010/2010 and MODULARANALYTICS E170 immunoassayanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Buffered equine serum withsynthetic 1-39 ACTH.</td><td rowspan=1 colspan=1>Buffered equine serum withrecombinant human Prolactin from E.Coli</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Reconstitute the contents withexactly 2.0 mL distilled water ordeionized water. Allow the bottleto stand closed for 15 minutes. Mixby inversion to ensurehomogeneity.</td><td rowspan=1 colspan=1>Reconstitute the contents with exactly1.0 mL distilled or deionized water.Allow the bottle to stand closed for 15minutes. Mix by inversion to ensurehomogeneity.</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Standardized gravimetrically withsynthethic ACTH produced atRoche.</td><td rowspan=1 colspan=1>Standardized against the 3&#x27;d IRP WHOReference Standard 84/500.</td></tr></table>

510(k) Summary, Continued

Substantial equivalence - differences   

<table><tr><td rowspan=1 colspan=3>PreciControl Comparison</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsy PreciControl ACTH</td><td rowspan=1 colspan=1>Predicate DeviceElecsys PreciControl Troponin T</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Used for quality control of theElecsys ACTH immunoassay onthe Elecsys immunoassayanalyzers.</td><td rowspan=1 colspan=1>Used for quality control of the ElecsysTroponin T (Cardiac T) immunoassayon the Elecsys immunoassay systems.</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Equine serum with added syntheticACTH</td><td rowspan=1 colspan=1>Troponin T (recombinant, human) inhuman serum</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 2-8°C up to the statedexpiration dateReconstituted:On the analyzer at 20 - 25°C: Up tothree hours.-20 °C : One month (freeze onlyonce)After thawing: Use only once.</td><td rowspan=1 colspan=1>Unopened:Store at 2-8°C up to the statedexpiration dateReconstituted:On the analyzer at 20 - 25°C: Up tofive hours.-20 °C : Three months (freeze onlyonce)After thawing: Use only once.At 2-8°C: Two weeks</td></tr></table>

# MAY 3 2006

Randy Johnson MT (ASCP) Regulatory Affairs Consultant Roche Diagnostics   
9115 Hague Road   
PO Box 50416   
Indianapolis, IN 46250-0416

Re: k060585 Trade/Device Name: Elecsys ACTH Test System Regulation Number: 21 CFR§862.1025 Regulation Name: Adrenocorticotropic hormone (ACTH) test system Regulatory Class: Class II Product Code: CKG, JIT, JJX Dated: March 6, 2006 Received: March 7, 2006

Dear Mr. Johnson:

We have reviewed your Section $5 1 0 ( \mathbf k )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/77dd170529ab483d017ca13c2ac5618905e2fa4d74f583a8da322f131ce5ad6c.jpg)

Alberto Gutierrez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K060585

Device Name: Elecsys ACTH Test System

Indications For Use:

Elecsys ACTH Assay:   
Immunoasssay for the in vitro quantitative determination of adrenocorticotropic hormone (ACTH) in human EDTA plasma. The electrochemiluminescence immunoassay   
"ECLIA" is intended for use on the Roche Elecsys 1010/2010 and MODULAR   
ANALYTICS E 170 (Elecsys module) immunoassay analyzers. ACTH measurements are used in the differential diagnosis and treatment of certain disorders of the adrenal glands such as Cushings syndrome, adrenocortical insufficiency, and the ectopic ACTH syndrome.

Elecsys ACTH CalSet is used for calibrating the quantitative Elecsys ACTH assay on the Elecsys immunoassay analyzers.

Elecsys ACTH CalCheck: For use in the verification of the calibration established by the Elecsys ACTH reagent on Elecsys 1010/2010 and MODULAR E170 immunoassay analyzers.

Elecsys PreciControl ACTH is used for quality control of the Elecsys ACTH immunoassay on the Elecsys immunoassay analyzers.

Prescription Use XXX AND/OR (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Replacement Page 28